<DOC>
	<DOCNO>NCT00291850</DOCNO>
	<brief_summary>A single arm , open-label phase II appropriate evaluate efficacy safety dose - dense combination paclitaxel cisplatin support pegfilgrastim neo-adjuvant chemotherapy patient population .</brief_summary>
	<brief_title>Phase II Trial Dose-dense Paclitaxel Cisplatin Neo-adjuvant Chemotherapy Operable Stage II IIA NSCLC</brief_title>
	<detailed_description>This open-label , single-arm Phase II study dose-dense regimen paclitaxel cisplatin support pegfilgrastim neo-adjuvant chemotherapy patient operable stage II , IIA NSCLC . Paclitaxel administer via intravenous infusion approximately 3 hour dose 175mg/m2 Day 1 14-day cycle . Cisplatin 75mg/m2 give via intravenous infusion day 1 ( paclitaxel ) accord institutional guideline . Pegfilgrastim ( Neulasta ) fix dose 6mg ( 0.6mL 10mg/mL solution ) single subcutaneous injection Day 2 study cycle . All drug give 2-weekly cycle . Three cycle pre-operative chemotherapy plan .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>histologic cytologic diagnosis NSCLC Presence clinical Stage IIA , IIB IIA disease tumor amenable curative surgical resection Patients clinically measurable lesion enrol study . No prior tumor therapy Performance status 01 ECOG Scale Patients compliance geographic proximity allow adequate followup . Medical fitness patient , include respiratory function , adequate radical NSCLC surgery . Presence clinical Stage IIIA disease , accord revision Mountain CF American Joint Committee Cancer . Treatment within last 30 day investigational drug . Cocurrent administration tumor therapy , include radiotherapy , cytotoxic chemotherapy , immunotherapy , molecular target therapy . Active infection opinion investigator would compromise patient ` ability tolerate therapy . pregnancy/breast feed Serious concomitant disorder would compromise safety patient compromise patient ability complete study , discretion investigator . poorly control diabetes mellitus Second primary malignancy clinically detectable time consideration study enrollment . History significant neurological mental disorder , include seizure dementia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>NSCLC</keyword>
</DOC>